183208-54-0

Basic information

• Product Name: 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine
• Synonyms: 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine
• CAS NO: 183208-54-0
• Molecular Formula: C10H12BrN3
• Molecular Weight: 254.13
• Mol File: 183208-54-0.mol

Chemical Properties

• Boiling Point: 340.63°C at 760 mmHg
• Flash Point: 159.808°C
• Appearance: /
• Density: 1.514g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine(183208-54-0)
• EPA Substance Registry System: 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine(183208-54-0)

Safety Data

• Hazardous Substances Data: 183208-54-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine is used as a therapeutic agent for the treatment of various diseases, particularly cancer and inflammatory disorders. Its ability to selectively inhibit the BET family of proteins leads to the suppression of tumor growth and inflammation, making it a promising candidate for further research and development in the pharmaceutical industry.
Used in Cancer Treatment:
1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine is used as an anticancer agent, targeting the BET proteins that play a role in the regulation of gene expression and cell proliferation. By inhibiting these proteins, LSN3213128 can potentially suppress tumor growth and improve outcomes for patients with various types of cancer.
Used in Inflammatory Disorder Treatment:
1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine is used as an anti-inflammatory agent, targeting the BET proteins that are involved in the regulation of inflammatory responses. Its ability to inhibit these proteins may help in reducing inflammation and managing inflammatory disorders.

InChI:InChI=1/C10H12BrN3/c1-14(2)6-7-4-12-10-9(7)3-8(11)5-13-10/h3-5H,6H2,1-2H3,(H,12,13)

Upstream product

• 50-00-0 formaldehyd 
• 506-59-2 N,N-dimethylammonium chloride 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 757978-34-0 5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
• 757978-33-9 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxaldehyde 

Relevant articles and documents

Alkenyl compound and its method and use thereof

The invention provides a new substituted alkenyl compound, pharmaceutically acceptable salts of the new substituted alkenyl compound, a medicinal preparation of the new substituted alkenyl compound, and application of the new substituted alkenyl compound, the pharmaceutically acceptable salts and the medicinal preparation of the new substituted alkenyl compound in aspects of regulating the activity of protein kinase and regulating the intercellular or intracellular signal response. The invention also relates to a medicament composition containing the compound at the same time, and relates to a method for treating high-proliferative diseases of mammals especially the human by using the medicament composition.

ALKENYL COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkenyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Compounds and methods for development of Ret modulators

Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and strucural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.

JNK INHIBITORS

The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of n